JOP20220021A1 - تخليق على مقياس العملية لمثبط كاليكرين في البلازما - Google Patents

تخليق على مقياس العملية لمثبط كاليكرين في البلازما

Info

Publication number
JOP20220021A1
JOP20220021A1 JOP/2022/0021A JOP20220021A JOP20220021A1 JO P20220021 A1 JOP20220021 A1 JO P20220021A1 JO P20220021 A JOP20220021 A JO P20220021A JO P20220021 A1 JOP20220021 A1 JO P20220021A1
Authority
JO
Jordan
Prior art keywords
plasma
scale synthesis
kallikrein inhibitor
kallikrein
inhibitor
Prior art date
Application number
JOP/2022/0021A
Other languages
Arabic (ar)
English (en)
Inventor
Yahya El-Kattan
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of JOP20220021A1 publication Critical patent/JOP20220021A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
JOP/2022/0021A 2019-08-06 2020-08-05 تخليق على مقياس العملية لمثبط كاليكرين في البلازما JOP20220021A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962883396P 2019-08-06 2019-08-06
PCT/US2020/044921 WO2021026182A1 (en) 2019-08-06 2020-08-05 Process-scale synthesis of a plasma kallikrein inhibitor

Publications (1)

Publication Number Publication Date
JOP20220021A1 true JOP20220021A1 (ar) 2023-01-30

Family

ID=74504082

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0021A JOP20220021A1 (ar) 2019-08-06 2020-08-05 تخليق على مقياس العملية لمثبط كاليكرين في البلازما

Country Status (26)

Country Link
US (1) US12503443B2 (enExample)
EP (1) EP4010320A4 (enExample)
JP (1) JP7626751B2 (enExample)
KR (1) KR102928815B1 (enExample)
CN (1) CN114206839B (enExample)
AR (1) AR119617A1 (enExample)
AU (1) AU2020324422B2 (enExample)
BR (1) BR112022002060A2 (enExample)
CA (1) CA3149176A1 (enExample)
CL (2) CL2022000264A1 (enExample)
CO (1) CO2022002392A2 (enExample)
CR (1) CR20220092A (enExample)
DO (1) DOP2022000027A (enExample)
EC (1) ECSP22016209A (enExample)
GE (2) GEAP202515893A (enExample)
IL (1) IL290113B2 (enExample)
JO (1) JOP20220021A1 (enExample)
MX (1) MX2022001608A (enExample)
PE (1) PE20221009A1 (enExample)
PH (1) PH12022550221A1 (enExample)
PY (1) PY2042865A (enExample)
TN (1) TN2022000028A1 (enExample)
TW (1) TWI881995B (enExample)
UA (1) UA130182C2 (enExample)
UY (1) UY38826A (enExample)
WO (1) WO2021026182A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
EP4010320A4 (en) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Process-scale synthesis of a plasma kallikrein inhibitor
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
WO1991012779A1 (en) 1990-02-28 1991-09-05 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE60034447T2 (de) 2000-08-11 2008-02-14 Wilex Ag Nicht-kovalente Urokinase-und Angiogenese-Inhibitoren
US7038057B2 (en) 2001-08-13 2006-05-02 E.I. Du Pont De Nemours And Company Substituted 1H-dihydropyrazoles, their preparation and use
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
KR101687743B1 (ko) 2008-12-18 2016-12-19 바이엘 인텔렉쳐 프로퍼티 게엠베하 살해충제로서의 테트라졸 치환된 안트라닐산 아미드
CN102464701B (zh) 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
DK2909181T3 (da) 2012-10-16 2017-11-20 Tolero Pharmaceuticals Inc PKM2-modulatorer og fremgangsmåder til anvendelse deraf
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
EP4010320A4 (en) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Process-scale synthesis of a plasma kallikrein inhibitor

Also Published As

Publication number Publication date
AU2020324422B2 (en) 2026-02-26
JP7626751B2 (ja) 2025-02-04
TWI881995B (zh) 2025-05-01
KR20220044276A (ko) 2022-04-07
IL290113B1 (en) 2025-04-01
BR112022002060A2 (pt) 2022-06-07
GEAP202515893A (en) 2025-02-25
CO2022002392A2 (es) 2022-04-08
UA130182C2 (uk) 2025-12-10
AR119617A1 (es) 2021-12-29
WO2021026182A1 (en) 2021-02-11
EP4010320A1 (en) 2022-06-15
IL290113B2 (en) 2025-08-01
CR20220092A (es) 2022-06-03
PE20221009A1 (es) 2022-06-15
PH12022550221A1 (en) 2022-12-19
IL290113A (en) 2022-03-01
PY2042865A (es) 2021-05-05
KR102928815B1 (ko) 2026-02-19
CL2022000264A1 (es) 2022-10-21
GEP20257777B (en) 2025-07-10
EP4010320A4 (en) 2023-08-16
ECSP22016209A (es) 2022-06-30
CL2023000942A1 (es) 2023-11-24
US12503443B2 (en) 2025-12-23
TW202120481A (zh) 2021-06-01
DOP2022000027A (es) 2022-05-31
CN114206839B (zh) 2025-03-07
TN2022000028A1 (en) 2023-10-09
UY38826A (es) 2021-02-26
US20220289683A1 (en) 2022-09-15
AU2020324422A1 (en) 2022-03-17
CN114206839A (zh) 2022-03-18
CA3149176A1 (en) 2021-02-11
MX2022001608A (es) 2022-03-11
JP2022543419A (ja) 2022-10-12

Similar Documents

Publication Publication Date Title
CO2019010035A2 (es) Síntesis de inhibidor de mcl-1
EP4495113A4 (en) KIF18A INHIBITOR
DK4031547T3 (da) Plasmakallikreininhibitorer og anvendelser deraf
IL286352A (en) Novel small molecule inhibitors of tead transcription factors
LT3880670T (lt) Pagrindinio tarpinio kras g12c inhibitoriaus junginio patobulinta sintezė
EP4434979A4 (en) KIF18A INHIBITOR
ECSP22016209A (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso
JOP20220075A1 (ar) مثبطات عامل d المكمل عن طريق الفم
IL289764A (en) Plasma kallikrein inhibitors
EP4168398A4 (en) TYK-2 INHIBITOR
JOP20210036A1 (ar) مثبطات او- جليكوبروتين-2-أسيتاميدو-2-ديوكسي-3-دي-جلوكوبيرانوسيداز
IL314221A (en) Synthesis of a kif18a inhibitor
IL318656A (en) Main protease inhibitors of SARS-COV2
IL282454A (en) Crystalline salts of a plasma kallikrein inhibitor
DK4288036T3 (da) Formuleringer af en plasmakallikreinhæmmer
CA3264993A1 (en) Methanogen inhibitors
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
JP1729409S (ja) ガス分配プレート
JP1757121S (ja) ミュージックシンセサイザー
EP4424177A4 (en) Sars-cov-2 proliferation inhibitor
DK4323338T3 (da) TEAD-hæmmere
HUE057912T2 (hu) Plazma kallikrein inhibitort tartalmazó dózisformák
IL318607A (en) Plasma kallikrein inhibitors
EP4469458A4 (en) PLASMA KALLICEREIN INHIBITORS
HK40075883A (en) Process-scale synthesis of a plasma kallikrein inhibitor